The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient-level meta-analysis of randomized trials of aromatase inhibitors (AI) versus tamoxifen (Tam).
John F. Forbes
Honoraria - AstraZeneca; Novartis
Mitchell Dowsett
Research Funding - AstraZeneca; Pfizer
Rosie Bradley
No relevant relationships to disclose
James N. Ingle
No relevant relationships to disclose
Tomohiko Aihara
No relevant relationships to disclose
Judith M. Bliss
Honoraria - Pfizer
Research Funding - Pfizer
Francesco Mario Boccardo
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Alan S. Coates
No relevant relationships to disclose
R. Charles Coombes
No relevant relationships to disclose
Jack M. Cuzick
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Peter Christian Dubsky
Honoraria - AstraZeneca; Novartis; Pfizer
Michael Gnant
No relevant relationships to disclose
Manfred Kaufmann
No relevant relationships to disclose
Lucy S Kilburn
No relevant relationships to disclose
Francesco Perrone
Honoraria - Novartis; Pfizer
Daniel Rea
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - Novartis; Pfizer
Research Funding - Pfizer
Beat J. K. Thurlimann
Stock Ownership - Novartis
Cornelis J. H. Van De Velde
No relevant relationships to disclose
Christina Davies
No relevant relationships to disclose
Richard G. Gray
No relevant relationships to disclose